These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31759363)

  • 21. Association of the neutrophil-to-lymphocyte ratio and prostate cancer detection rates in patients via contemporary multi-core prostate biopsy.
    Oh JJ; Kwon O; Lee JK; Byun SS; Lee SE; Lee S; Hong SK
    Asian J Androl; 2016; 18(6):937-941. PubMed ID: 26470836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
    Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
    Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive Value of the Platelet-To-Lymphocyte Ratio in Diagnosis of Prostate Cancer.
    Yuksel OH; Urkmez A; Akan S; Yldirim C; Verit A
    Asian Pac J Cancer Prev; 2015; 16(15):6407-12. PubMed ID: 26434851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of percent free prostate-specific antigen density to improve the specificity for detecting prostate cancer in patients with normal rectal examinations and intermediate prostate-specific antigen levels.
    Baltaci S; Aksoy H; Türkölmez K; Elhan AH; Ozden E; Göğüş O
    Urol Int; 2003; 70(1):36-41. PubMed ID: 12566813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer.
    Fowler JE; Bigler SA; Miles D; Yalkut DA
    J Urol; 2000 Mar; 163(3):813-8. PubMed ID: 10687983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
    Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Primary circulating prostate cells, age and prostatic volumen predict the presence of prostate cancer in men with indication of a second prostate biopsy.].
    Murray NP; Aedo S; Reyes E; Fuentealba C; Jacob O
    Arch Esp Urol; 2019 Jan; 72(1):16-24. PubMed ID: 30741649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel nomogram combined PIRADS v2 and neutrophil-to-lymphocyte ratio to predict the risk of clinically significant prostate cancer in men with PSA < 10 ng/ml at first biopsy.
    Sun J; Zhang Z; OuYang J
    Urol Oncol; 2020 May; 38(5):401-409. PubMed ID: 31870724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutrophil-to-lymphocyte and neutrophil-to-monocyte rates in the decision for a prostate re-biopsy in patients with a previous benign pathology and consistently 2,5-10 ng/ml PSA value.
    Ceylan Y; Günlüsoy B; Degirmenci T; Bolat D; Kozacioglu Z; Vardar E; Topçu YK; Polat S
    Arch Esp Urol; 2016 Nov; 69(9):627-635. PubMed ID: 27845694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
    Catalona WJ; Smith DS; Ornstein DK
    JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
    Morote J; Raventós CX; Lorente JA; Lopez-Pacios MA; Encabo G; de Torres I; Andreu J
    J Urol; 1997 Aug; 158(2):502-4. PubMed ID: 9224333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Value of prostate-specific antigen (PSA) mass ratio in the detection of prostate cancer in men with PSA levels of ≤10 ng/mL.
    Hong SK; Oh JJ; Byun SS; Hwang SI; Choo MS; Lee SE
    BJU Int; 2012 Jul; 110(2 Pt 2):E81-5. PubMed ID: 22093144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Change in Neutrophil Lymphocyte Ratio from the First to the Last Repeat Prostate Biopsy Proposed as a Marker of Carcinogenesis.
    Hashimoto M; Matsumura N; Ohzeki T; Hongo S; Sugimoto K; Shimizu N; Mori Y; Minami T; Nozawa M; Nose K; Tahara H; Yoshimura K; Uemura H
    Urol Int; 2018; 101(1):74-79. PubMed ID: 29909414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL.
    Babaian RJ; Fritsche H; Ayala A; Bhadkamkar V; Johnston DA; Naccarato W; Zhang Z
    Urology; 2000 Dec; 56(6):1000-6. PubMed ID: 11113747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective evaluation of prostate specific antigen (PSA), PSA density, free-to-total PSA ratio and a new formula (prostate malignancy index) for detecting prostate cancer and preventing negative biopsies in patients with normal rectal examinations and intermediate PSA levels.
    Dinçel C; Caşkurlu T; Taşçi AI; Cek M; Sevin G; Fazlioğlu A
    Int Urol Nephrol; 1999; 31(4):497-509. PubMed ID: 10668945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biopsy-proved prostate cancer in 100 consecutive men with benign digital rectal examination and elevated serum prostate-specific antigen level. Prevalence and pathologic characteristics.
    Guthman DA; Wilson TM; Blute ML; Bergstralh EJ; Zincke H; Oesterling JE
    Urology; 1993 Aug; 42(2):150-4. PubMed ID: 7690170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.
    Catalona WJ; Richie JP; deKernion JB; Ahmann FR; Ratliff TL; Dalkin BL; Kavoussi LR; MacFarlane MT; Southwick PC
    J Urol; 1994 Dec; 152(6 Pt 1):2031-6. PubMed ID: 7525994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimum PSA reflex-range.
    Benecchi L
    Arch Ital Urol Androl; 2006 Jun; 78(2):44-8. PubMed ID: 16929601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with psa levels between 2.6 and 10.0 ng/mL.
    Castro HAS; Iared W; Santos JEM; Solha RS; Shigueoka DC; Ajzen SA
    Int Braz J Urol; 2018; 44(4):709-716. PubMed ID: 29697929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma.
    Letran JL; Blase AB; Loberiza FR; Meyer GE; Ransom SD; Brawer MK
    J Urol; 1998 Aug; 160(2):426-9. PubMed ID: 9679891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.